Engineering Bispecifics at PEGS Europe 2019 presents truly novel engineering approaches such as new high throughput screening for target discovery, synergistic pair combinations and key bispecific parameters. In addition, engineering for improved targeting with proven functionality, enhanced potency and minimal tox will be showcased. It focuses on challenging areas such as crossing the blood brain barrier, ophthalmology, overcoming bacterial and viral resistance, and Treg selection. We present data-rich case studies that report on difficulties encountered and overcome.

Preliminary Agenda

INSIGHTS INTO BISPECIFIC MECHANISMS THAT WORK

KEYNOTE PRESENTATION: Biophysical Characterization to Determine the Impact of Different Mechanisms of Bispecific Molecules

Andreas Plueckthun, PhD, Professor & Director, Biochemistry, University of Zurich

Lisbon Wasn’t Built in a Day – Alternative Scaffolds Gain Momentum

H. Kaspar Binz, PhD, Binz Biotech Consulting

NEW PLATFORMS FOR DISCOVERY, PRODUCTION AND IDENTIFICATION OF SYNERGISTIC TARGET PAIRS

A Simple IgG-like Discovery Platform for a Complex IgG-Like (1+1) Format

Régis Cebe, MSc, Scientific Technical Leader, Novartis Biologic Centre, Novartis Institute of Biomedical Research

A New Platform for the Identification of Synergistic Bispecific Combinations

Elke Glasmacher, PhD, Head, Immunobiology, Large Molecule Research, pRED, Roche Innovation Center

FOCUS ON T-CELL ACTIVATION, PK, AFFINITY AND MAXIMIZING THE THERAPEUTIC INDEX

Dual Agonist Bispecific Antibody Targeting OX40 and CD137 Mediates Anti-Tumour Immunity and Synergises with PD-1/PD-L1 Blockade to Improve Survival in a Syngeneic Mouse Model

Mihriban Tuna, PhD, SVP, Drug Discovery, F-star

Optimization of Preclinical Safety and Efficacy of Anti-HER2/CD3

Teemu Junttila, PhD, Senior Scientist, Translational Oncology, Genentech, Inc.

Concept to Clinic: Development of Fc-Containing XmAb® Bispecific Antibodies for Immunotherapy

Umesh Muchtal, PhD, Director, Molecular Biology & Protein Sciences Xencor, Inc.

Targeted Antibody-Prodrugs

Ulrich Brinkmann, PhD, Expert Scientist, Large Molecule Research, Roche Pharma Research & Early Development, Roche

TCER® Platform: Targeting of Tumor-Specific HLA Ligands using T Cell Receptor Bispecifics 

Sebastian Bunk, PhD, Immunology, Immatics Biotechnologies GmbH

ENGINEERING FOR AUTOIMMUNE DISEASE AND TO OVERCOME VIRAL RESISTANCE

Preclinical Development of Xmab27564, a Long-Acting IL2-Fc Fusion Protein, as a Novel Treg-Selective Therapy for Autoimmune Diseases

Suzanne Schubbert, PhD, Lead Scientist, Cell Biology, Xencor, Inc.

Multi-Specific Agent to Overcome Potential Resistance to Influenza

Mark Chiu, PhD, Associate Director, Structural Biology, Janssen

HIGH THROUGHPUT SCREENING APPROACHES FOR BISPECIFICS

Bispecific Target Discovery by High Throughput Functional Screening

Pallavi Bhatta. PhD, Principal Scientist, Bispecific Target Discovery, UCB

NestLink Technology to Determine Key Pharmacokinetic Parameters of Hundreds of Bispecifics Simultaneously

Pascal Egloff, PhD, Platform Leader, Medical Microbiology, University of Zurich

CROSSING THE BLOOD BRAIN BARRIER

Brain Penetrant Bispecific Agonist Antibodies to Neurotrophin Receptors Trkb and Trkc

Frank S. Walsh, PhD, CEO, Ossianix, Inc.



* The program is subject to change without notice, due to unforeseen reason.


Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean